logo
  

Endocyte Inc. (ECYT) Has Jumped To A New High After Bought By Novartis

Endocyte Inc. (ECYT) announced Thursday morning that it has agreed to be acquired by Novartis for $24 per share in cash, or approximately $2.1 billion.

Endocyte has gapped open sharply higher this morning and is now up 7.81 at $23.37 on the highest volume in 7 1/2 months. The stock has leaped to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT